New treatment approach for relapsed or refractory Hodgkin lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates a treatment strategy for patients with relapsed or refractory Hodgkin lymphoma who have high-risk factors. The approach combines Brentuximab Vedotin with PD-1 blockade followed by autologous stem cell transplantation and maintenance therapy. The study aims to evaluate progression-free survival and metabolic response rates in this patient population, addressing a significant gap in current treatment options. By focusing on immunotherapy, the trial seeks to improve outcomes while minimizing toxicity compared to standard treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Relapsed/refractory Hodgkin lymphoma to ABVD with definition of high risk.
2. Age ≥ 18 years and ≤ 90 years.
3. Adequate liver function, defined as:

   * Total serum bilirubin ≤ 1.5 x upper limit of normal (ULN)
   * Serum aspartate aminotransferase (AST) ≤ 3.0 x ULN
   * Serum alanine aminotransferase (ALT) ≤ 3.0 x ULN
4. Adequate renal functions, defined as:

   • Serum creatinine ≤ 1.5x ULN or glomerular filtration rate \> 50ml/min.
5. ECOG performance status ≤ 3
6. Women of reproductive potential should have a serum pregnancy test or negative urine.
7. Prior signature of the informed consent.

Exclusion Criteria:

1. Voluntary withdrawal from the study.
2. Develop grade 3 or 4 toxicity according to the INH scale.
3. Loss of follow-up

Where it's running

• Hospital Regional Alta Especialidad Bajio
  León, Guanajuato, Mexico Recruiting

Study contacts

• Study coordinator: Lauro Fabián Amador, PhD
• Email: lafab2013@gmail.com
• Phone: 4772697907

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BrECADD for stage 2B–III classical Hodgkin lymphoma

  This tests the BrECADD chemotherapy combination in adults 18–60 with stage 2B (with risk factors) or stage III classical Hodgkin lymphoma and uses ctDNA to help track treatment response.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT07002216

• Combining brentuximab vedotin with standard chemotherapy for Hodgkin lymphoma in adults

  This study is testing if adding a new drug called brentuximab vedotin to standard chemotherapy can help adults with untreated Hodgkin lymphoma feel better and improve their treatment results.

  Recruiting at 5 sites Phase 4 Takeda · Vijayawada, Andhra Pradesh and 10 other locations · NCT06831370

• Survey of Brentuximab Vedotin for treating pediatric Hodgkin Lymphoma

  This study looks at how well Brentuximab Vedotin works with standard treatment for kids with Hodgkin lymphoma and checks for any side effects they might have.

  Recruiting Takeda · Tokyo, Tokyo · NCT05481437

• Comparing new drugs to standard treatment for relapsed Hodgkin lymphoma

  This study is testing if new drugs Pembrolizumab and Brentuximab vedotin work better than standard treatment for people with relapsed Hodgkin lymphoma.

  Recruiting at 18 sites Phase 2 Canadian Cancer Trials Group · Concord, New South Wales and 17 other locations · NCT05180097

• Brentuximab vedotin for early stage Hodgkin lymphoma treatment

  This study is testing if adding a new drug called brentuximab vedotin to standard chemotherapy can help people with early-stage Hodgkin lymphoma do better in their treatment.

  Recruiting at 72 sites Phase 3 University College, London · Stanford, California and 71 other locations · NCT04685616

• New ways to diagnose lymphoma and multicentric Castleman disease in people living with HIV

  This study tests a quick, point-of-care nucleic acid test to help diagnose lymphoma and multicentric Castleman disease in people living with HIV in sub-Saharan Africa.

  Recruiting Indiana University · Lilongwe · NCT07793006

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.